What Is Zepbound?
Published May 2, 2026 · 4 minute read
Zepbound is a brand name for the active ingredient tirzepatide. It is prescribed for chronic weight management and obstructive sleep apnea. Here is a breakdown of the molecule, brand, FDA label, and how it differs from other medications.
Key Takeaways
- Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist.
- FDA labeling covers chronic weight management and certain OSA use in adults.
- Mounjaro also contains tirzepatide, but it is a different brand with different approved indications.
1. What Is Zepbound?
Zepbound is an injectable prescription medicine containing the active ingredient tirzepatide. According to the DailyMed label, Zepbound is indicated-alongside a reduced-calorie diet and increased physical activity-to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related comorbid condition.
The label also indicates Zepbound for moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
2. Tirzepatide vs. Zepbound
Tirzepatide is the active ingredient in Zepbound. The DailyMed label describes tirzepatide as a dual GIP receptor and GLP-1 receptor agonist, meaning it selectively binds to and activates both the GIP and GLP-1 receptors.
“Zepbound” refers to the specific brand and its FDA-labeled uses, while “tirzepatide” refers to the molecule itself. For more background on GLP terminology, see GLP-1 vs GLP-2 vs GLP-3. Zepbound is not a GLP-2 or GLP-3 product.
3. What Does Dual GIP/GLP-1 Mean?
Dual GIP/GLP-1 means tirzepatide is designed to activate two incretin-related receptor pathways: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The FDA states that Zepbound activates receptors for both hormones to reduce appetite and food intake.
It is not two separate medicines mixed together; rather, the single active ingredient targets two distinct receptors. Although often casually referred to as just a “GLP-1 drug,” it is more accurately classified as a dual GIP and GLP-1 receptor agonist.
5. Zepbound for Obstructive Sleep Apnea (OSA)
In December 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, to be used alongside a reduced-calorie diet and increased physical activity.
This approval was based on two randomized, double-blind, placebo-controlled studies of 469 adults without type 2 diabetes. One study enrolled people using positive airway pressure therapy, and the other enrolled people unable or unwilling to use it.
The measured endpoint was the apnea-hypopnea index (AHI), which counts apnea and hypopnea events per hour of sleep. Participants receiving Zepbound experienced statistically significant AHI reductions compared with placebo, an improvement the FDA noted was likely related to overall body-weight reduction.
6. Clinical Trial Data for Weight Management
The FDA’s chronic weight-management approval was supported by two 72-week trials with 2,519 participants receiving Zepbound and 958 receiving a placebo. In the larger trial, which enrolled adults without diabetes, the FDA reported an average body-weight loss of 18% for the highest approved dose group compared to the placebo group.
7. What Is Zepbound FAQ
What is Zepbound in simple terms?
Zepbound is a prescription medicine that contains tirzepatide. FDA labeling says it is used with reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity or certain adults with overweight, and for moderate to severe OSA in adults with obesity.
Is Zepbound the same as Mounjaro?
No. Zepbound and Mounjaro both contain tirzepatide, but they are different brands with different labeled contexts. DailyMed lists Zepbound for weight reduction and certain OSA use, while Mounjaro is listed for glycemic control in type 2 diabetes.
Why is Zepbound called a dual GIP/GLP-1 medicine?
The Zepbound label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist. That means the molecule is designed to selectively bind and activate both receptor pathways.
Is Zepbound approved for obstructive sleep apnea?
Yes. In December 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity.